UNIverse - Public Research Portal

[FG] European Center for Pharmaceutical Medicine (ECPM)

Projects & Collaborations

51 found
Show per page
Project cover

Health economic analysis alongside DROPIT trial

Research Project  | 2 Project Members

Worldwide, proton pump inhibitors (PPIs) are frequently prescribed, and their use is continuingly increasing. PPI use is often inappropriate, they are prescribed for excessive durations or inadequate indications which contribute to adverse health outcomes. Reducing inappropriate PPIs could improve health and reduce human and financial costs. Limited studies have evaluated patient-focused deprescribing interventions to reduce inappropriate PPIs in the primary care setting. The involvement of general practitioners (GPs) and patients in deprescribing (to stop or reduce PPIs) is a necessity. Aims of the DROPIT trial: a) To investigate the effectiveness of an intervention for patients and GPs to deprescribe inappropriate PPIs in adults i) On the co-primary outcomes: - change from baseline in the dose of proton pump inhibitors (PPIs) at the 12-month follow-up - change from baseline in the Reflux Disease Questionnaire (RDQ) at the 12-month follow-up ii) Secondary outcomes: individual components of the co-primary outcomes, atypical gastrointestinal symptoms, diagnoses and conditions linked to PPI use, number and type of concurrent medications, medication adherence, prescribing of PPIs and alternative anti-reflux treatments, healthcare utilization, health-related quality of life, and side effects related to PPI deprescribing b) To evaluate the implementation of the intervention as well as GPs' and patients' intervention fidelity in a mixed-methods process evaluation c) To evaluate the cost-effectiveness of the trial intervention through health economic analyses. This part is in the responsibility of Uni basel, Research Group M. Schwenkglenks

Project cover

SwissPandemic&AmR-Health Economy Awareness Detect (Flagship project), Subproject 4: Societal and Health Economics

Research Project  | 2 Project Members

The SPEARHEAD project, led by the University of Basel Innovation Office with funding from the Innosuisse Flagship programme, brings together research institutions (University of Basel, SUPSI), university hospitals (UKBB, USB, CHUV), and industry partners (Novartis, SwissRe, SWICA) to develop novel approaches to strengthen antimicrobialsStewardship. The project builds on existing initiatives and expertise in pandemic response to rapidly deploy digital solutions to mitigate the clinical, economic, and societal impacts of antimicrobial resistance (AMR) by enabling real-time data flow to and from decision-makers, better use of big data for risk stratification, timely diagnostics that can leapfrog centralized laboratory infrastructure, citizen and community engagement, and early consideration of resource needs and efficiency to inform prioritization of candidate technologies. The tools being developed within SPEARHEAD are aimed to be easily adaptable to address future emerging infections and thereby result in a more resilient healthcare system and society. ECPM leads the Societal and Health Economics work package of SPEARHEAD that aims to analyse the cost-effectiveness of the piloted solutions, inform their scale-up, and consider their broader societal and equity implications.

Project cover

Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

Research Project  | 2 Project Members

Background The EQ-5D-3L and EQ-5D-5L are two generic health-related quality of life measures, which may be used in clinical and health economic research. They measure impairment in 5 aspects of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The aim of this study was to assess the performance of the EQ-5D-3L and EQ-5D-5L in measuring the self-reported health status of older patients with substantial multimorbidity and associated polypharmacy. Methods Between 2017 and 2019, we administered EQ-5D-3L and EQ-5D-5L to a subset of patients participating in the OPERAM trial at 6 months and 12 months after enrolment. The OPERAM trial is a two-arm multinational cluster randomised controlled trial of structured medication review assisted by a software-based decision support system versus usual pharmaceutical care, for older people (aged ≥ 70 years) with multimorbidity and polypharmacy. In the psychometric analyses, we only included participants who completed the measures in full at 6 and 12 months. We assessed whether responses to the measures were consistent by assessing the proportion of EQ-5D-5L responses, which were 2 or more levels away from that person's EQ-5D-3L response. We also compared the measures in terms of informativity, and discriminant validity and responsiveness relative to the Barthel Index, which measures independence in activities of daily living. Results 224 patients (mean age of 77 years; 56% male) were included in the psychometric analyses. Ceiling effects reported with the EQ-5D-5L (22%) were lower than with the EQ-5D-3L (29%). For the mobility item, the EQ-5D-5L demonstrated better informativity (Shannon's evenness index score of 0.86) than the EQ-5D-3L (Shannon's evenness index score of 0.69). Both the 3L and 5L versions of EQ-5D demonstrated good performance in terms of discriminant validity, i.e. (out of all items of the EQ-5D-3L and EQ-5D-5L, the pain/discomfort and anxiety/depression items had the weakest correlation with the Barthel Index. Both the 3L and 5L versions of EQ-5D demonstrated good responsiveness to changes in the Barthel Index. Conclusion Both EQ-5D-3L and EQ-5D-5L demonstrated validity and responsiveness when administered to older adults with substantial multimorbidity and polypharmacy who were able to complete the measures.

Project cover

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Research Project  | 2 Project Members

Gene therapy is one of the most promising treatment options for future advanced therapies in a broad range of diseases. Successful gene delivery requires the recognition of target cells as well as cytosolic and nucleosolic uptake of the gene. Currently, non-viral based gene delivery such as transfection reagents are only suitable for in vitro applications and clinical gene therapeutics delivery is accomplished via viral vectors, which still has major safety concerns and complex and costly manufacturing procedures, preventing future implementation for the treatment of diseases with large patients groups. In the last 15 years, a class of secondary plant metabolites has been discovered that selectively mediates endosomal escape and cytoplasmic delivery of macromolecules only at low endosomal pH, thereby inducing a 40-fold enhanced gene delivery efficacy, in vivo . The currently employed methods of applying endosomal escape enhancers and gene therapeutic product, however, do not ensure that both compounds are at the same time at the site of interaction. The ENDOSCAPE technology platform will develop and collect proof of concept for a non-viral gene delivery technology with increased synchronization (in time and place) of both compounds. Proof of concept of the ENDOSCAPE technology has a major impact on the therapeutic opportunities for current and future macromolecule drugs for a broad range of diseases. All this induces new biotech-based businesses; new research projects and creates new technology platforms for development of new macromolecule therapeutics for a broad range of disease indications. The non-viral bases ENDOSCAPE technology will enhance therapeutic efficacy with lower therapeutic dose thereby reducing costs of healthcare, improving the health of patients worldwide, and strengthening the competitive landscape of the EU in the worldwide quest for such an advanced technology.

Project cover

Projektevaluation: Prävention psychosozialer Belastungsfolgen in der Somatik: ein Modellprojekt zur kollaborativen Versorgung (SomPsyNet)

Research Project  | 6 Project Members

Evaluation des Projekts: Prävention psychosozialer Belastungsfolgen in der Somatik: ein Modellprojekt zur kollaborativen Versorgung (SomPsyNet)


Das durch Gesundheitsförderung Schweiz finanzierte Projekt wurde durch eine Evaluation begleitet. Das Ziel dieser war, die von Gesundheitsförderung Schweiz vorgegebenen Evaluationsbereiche (Konzept, Input, Umsetzung, Output, Outcome Multiplikatoren, Outcome Patient:innen, Impact) abzudecken. Das Vorgehen orientierte sich am Dokument «Wirkungsevaluation von Interventionen» von Gesundheitsförderung Schweiz. Die Evaluationstätigkeiten fanden im Zeitraum Januar 2020 bis Dezember 2023 statt und es wurden verschiedene Methoden verwendet. Die Konzept, Input, Umsetzung und Output-Evaluation, beinhaltete eine Kostenanalyse, sowie zwei Serien von Interviews beim Spitalpersonal zur Wahrnehmung der Situation von psychosozialen Belastungen bei somatischen Patient:innen sowie Erfolgsfaktoren und Hindernisse bei der Umsetzung des SCCMs. Der Outcome wurde durch eine On-line Umfrage bei rund 100 in das SCCM involvierten Personen erfasst. Des Weiteren, wurde die Wirksamkeit (Outcome sowie Impact) mittels einer Stepped Wedge-Studie, die unter der Verantwortlichkeit des Projekträgers stand, bewertet. Die Studie evaluierte unter anderem, Veränderung der Lebensqualität von somatischen Patienten mit PB/PS sowie die Auswirkungen auf die monatlichen Behandlungskosten von Patient:innen mit psychosozialer Belastung.